Nadelmann 1986

Methods	D: crossover C: unclear B: double WD: 21/64 J: 1‐2‐1 DU: 4w/6+2x12w (no washout)/‐
Participants	N: 57/41 (67 entered baseline, 57 entered treatment phases) D: 35 migraine with, 27 migraine with and without aura C: Ad Hoc F: 83% A: 18‐60 years DU: not reported S: unclear, USA
Interventions	P: 80‐320 mg C: Placebo
Outcomes	R: not reported F: not reported AU: better with propranolol HI: better with propranolol AEs: more frequent with propranolol Dropouts‐AEs: 1st period: 0/28 vs. 0/29; pooled: 0/57 vs. 0/57 V: +
Notes	Detailed subgroup analyses
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear